Evidence for aldosterone-dependent growth of renal cell carcinoma

International Journal of Experimental Pathology

Volumn 95, Issue 4, 2014, Pages 244-250

  King, Sharon ^a   Bray, Susan ^a   Galbraith, Sarah ^a   Christie, Lesley ^a   Fleming, Stewart ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aldosterone; K RAS; Mineralocorticoid receptor; Renal cell carcinoma

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; K RAS PROTEIN; MINERALOCORTICOID RECEPTOR; PROTEIN KINASE B; RAF PROTEIN; SMALL INTERFERING RNA; SPIRONOLACTONE;

ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; KIDNEY CARCINOMA; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENAL CANCER CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING;

ALDOSTERONE; K-RAS; MINERALOCORTICOID RECEPTOR; RENAL CELL CARCINOMA;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ALDOSTERONE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; KIDNEY NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; RAS PROTEINS; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SPIRONOLACTONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904026481     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12074     Document Type: Article

References (45)

1. Alam N.A., Olpin S. & Leigh I.M. (2005) Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer. Br. J. Dermatol. 153, 11-17.
2. Bos J.L., Fearon E.R., Hamilton S.R. et al. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-297.
3. Capon D.J., Seeburg P.H., McGrath J.P. et al. (1983) Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304, 507-513.
4. Chow W.H. & Devesa S.S. (2008) Contemporary epidemiology of renal cell cancer. Cancer J. 14, 288-301.
5. Fleming S. (1993) The impact of genetics on the classification of renal carcinoma. Histopathology 22, 89-92.
6. Fleming S. (1999) Renal cancer genetics: von Hippel Lindau and other syndromes. Int. J. Dev. Biol. 43, 469-471.
7. Foster K., Prowse A., van den Berg A. et al. (1994) Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3, 2169-2173.
8. Gemmill R.M., Zhou M., Costa L., Korch C., Bukowski R.M. & Drabkin H.A. (2005) Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br. J. Cancer 92, 2266-2277.
9. Gnarra J.R., Tory K., Weng Y. et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90.
10. Grunewald K., Lyons J., Frohlich A. et al. (1989) High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer 43, 1037-1041.
11. Hii S.I., Nicol D.L., Gotley D.C., Thompson L.C., Green M.K. & Jonsson J.R. (1998) Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br. J. Cancer 77, 880-883.
12. Housley S.L., Lindsay R.S., Young B. et al. (2010) Renal carcinoma with giant mitochondria associated with germ-line mutation and somatic loss of the succinate dehydrogenase B gene. Histopathology 56, 405-408.
13. Kantachuvesiri S., Fleming S., Peters J. et al. (2001) Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J. Biol. Chem. 276, 36727-36733.
14. Kotelevtsev Y., Brown R.W., Fleming S. et al. (1999) Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 103, 683-689.
15. Kozma S.C., Bogaard M.E., Buser K. et al. (1987) The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res. 15, 5963-5971.
16. Lever A.F., Hole D.J., Gillis C.R. et al. (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352, 179-184.
17. Lever A.F., Hole D.J., Gillis C.R. et al. (1999) Is cancer related to hypertension or to its treatment? Clin. Exp. Hypertens. 21, 937-946.
18. Mariyama M., Kishi K., Nakamura K., Obata H. & Nishimura S. (1989) Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn. J. Cancer Res. 80, 622-626.
19. Masuzaki H., Yamamoto H., Kenyon C.J. et al. (2003) Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112, 83-90.
20. Matsumoto K., Tsuda H., Iwase T. et al. (1992) Absence of ras family point mutations at codons 12, 13 and 61 in N-ethyl-N-hydroxyethylnitrosamine- or N-nitrosomorpholine-induced renal cell tumors in rats. Jpn. J. Cancer Res. 83, 933-936.
21. McCoy M.S., Bargmann C.I. & Weinberg R.A. (1984) Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol. Cell. Biol. 4, 1577-1582.
22. Miro L., Perez-Bosque A., Maijo M., Amat C., Naftalin R.J. & Moreto M. (2013) Aldosterone induces myofibroblast EGF secretion to regulate epithelial colonic permeability. Am. J. Physiol. Cell Physiol. 304, C918-C926.
23. Miyajima A., Asano T. & Hayakawa M. (2001) Captopril restores transforming growth factor-beta type II receptor and sensitivity to transforming growth factor-beta in murine renal cell cancer cells. J. Urol. 165, 616-620.
24. Montgomery H.E., Kiernan L.A., Whitworth C.E. et al. (1998) Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J. Hypertens. 16, 635-643.
25. Nanus D.M., Mentle I.R., Motzer R.J., Bander N.H. & Albino A.P. (1990) Infrequent ras oncogene point mutations in renal cell carcinoma. J. Urol. 143, 175-178.
26. Parry L., Maynard J.H., Patel A. et al. (2001) Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br. J. Cancer 85, 1226-1230.
27. Pascual D. & Borque A. (2008) Epidemiology of kidney cancer. Adv. Urol. 2008, 782381.
28. Plowman S.J., Williamson D.J., O'Sullivan M.J. et al. (2003) While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol. Cell. Biol. 23, 9245-9250.
29. Plowman S.J., Berry R.L., Bader S.A. et al. (2006) K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. J. Exp. Clin. Cancer Res. 25, 259-267.
30. Prosperi M.T., Dupre G., Lidereau R. & Goubin G. (1990) Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. Cancer Lett. 51, 169-174.
31. Purdue M.P., Moore L.E., Merino M.J. et al. (2013) An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies. Int. J. Cancer 132, 2640-2647.
32. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S. & Khvorova A. (2004) Rational siRNA design for RNA interference. Nat. Biotechnol. 22, 326-330.
33. Rochlitz C.F., Peter S., Willroth G. et al. (1992) Mutations in the ras protooncogenes are rare events in renal cell cancer. Eur. J. Cancer 28, 333-336.
34. Schmidt L., Duh F.M., Chen F. et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73.
35. Staruschenko A., Patel P., Tong Q., Medina J.L. & Stockand J.D. (2004) Ras activates the epithelial Na(+) channel through phosphoinositide 3-OH kinase signaling. J. Biol. Chem. 279, 37771-37778.
36. Staruschenko A., Pochynyuk O.M., Tong Q. & Stockand J.D. (2005) Ras couples phosphoinositide 3-OH kinase to the epithelial Na+ channel. Biochim. Biophys. Acta 1669, 108-115.
37. Stockand J.D. (2002) New ideas about aldosterone signaling in epithelia. Am. J. Physiol. Renal. Physiol. 282, F559-F576.
38. Stockand J.D. & Meszaros J.G. (2003) Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am. J. Physiol. Heart Circ. Physiol. 284, H176-H184.
39. Stojanovic M., Goldner B. & Ivkovic D. (2009) Renal cell carcinoma and arterial hypertension. Clin. Exp. Nephrol. 13, 295-299.
40. Tong Q. & Stockand J.D. (2005) Receptor tyrosine kinases mediate epithelial Na(+) channel inhibition by epidermal growth factor. Am. J. Physiol. Renal. Physiol. 288, F150-F161.
41. Tong Q., Booth R.E., Worrell R.T. & Stockand J.D. (2004) Regulation of Na+ transport by aldosterone: signaling convergence and cross talk between the PI3-K and MAPK1/2 cascades. Am. J. Physiol. Renal. Physiol. 286, F1232-F1238.
42. Varela I., Tarpey P., Raine K. et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542.
43. Whitworth C.E., Fleming S., Cumming A.D. et al. (1994) Spontaneous development of malignant phase hypertension in transgenic Ren-2 rats. Kidney Int. 46, 1528-1532.
44. Wykoff C.C., Pugh C.W., Maxwell P.H., Harris A.L. & Ratcliffe P.J. (2000) Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19, 6297-6305.
45. Yakirevich E., Morris D.J., Tavares R. et al. (2008) Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study. Am. J. Surg. Pathol. 32, 874-883.